StemCell Institute (TSE:7096) Debt-to-Asset : 0.07 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is StemCell Institute Debt-to-Asset?

StemCell Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was 円67 Mil. StemCell Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was 円452 Mil. StemCell Institute's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was 円7,501 Mil. StemCell Institute's debt to asset for the quarter that ended in Mar. 2025 was 0.07.

StemCell Institute Debt-to-Asset Historical Data

The historical data trend for StemCell Institute's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemCell Institute Debt-to-Asset Chart

StemCell Institute Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Asset

Get a 7-Day Free Trial

0.07

StemCell Institute Quarterly Data
	Mar18	Mar19	Dec19	Mar20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Sep24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial														-	-	-	-	0.07

Competitive Comparison of StemCell Institute's Debt-to-Asset

For the Biotechnology subindustry, StemCell Institute's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StemCell Institute's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, StemCell Institute's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where StemCell Institute's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

StemCell Institute Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

StemCell Institute's Debt-to-Asset for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(67.227	+	451.735)	/	7500.939
	=	0.07

StemCell Institute's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(67.227	+	451.735)	/	7500.939
	=	0.07

StemCell Institute (TSE:7096) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

StemCell Institute Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of StemCell Institute's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

StemCell Institute Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemCell Institute (TSE:7096) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Shimbashi, Minato-ku, Tamuracho Building, Matsuoka, Tokyo, JPN, 105-0004

Website

https://www.stemcell.co.jp

StemCell Institute is engaged in Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's own cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood.

StemCell Institute Headlines

No Headlines